Search results for "REU"

showing 10 items of 1466 documents

Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake Inhibitors

1998

Pharmacokinetic interactions of clozapine and its metabolites N-desmethylclozapine and clozapine N-oxide with the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine were investigated in a prospective study in schizophrenic patients under steady-state conditions. Thirty patients were treated with clozapine at a target dose of 2.5 to 3.0 mg/kg of body weight. After gradual dose escalation, serum concentrations of clozapine and two metabolites were determined twice at 7-day intervals after steady-state conditions had been reached. Then, fluvoxamine (50 mg/day) or paroxetine (20 mg/day) was added in 16 and 14 patients, respectively. Serum concentrations of clozapine and …

AdultMaleAdolescentFluvoxaminePharmacologyPharmacokineticsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesProspective cohort studyClozapineClozapinebusiness.industrySmokingMiddle AgedDrug interactionParoxetineParoxetinePsychiatry and Mental healthFluvoxamineSchizophreniaFemaleSerotoninbusinessReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.

1998

A six-week double-blind placebo-controlled trial of fluvoxamine was undertaken in 46 patients suffering from panic disorder with or without agoraphobia diagnosed by DSM-III-R guidelines. Average daily dosage of fluvoxamine was 160 mg, with a highest permitted dose of 300 mg/day. Weekly evaluation included a diary in which the number, severity, and duration of full-blown and limited panic attacks and the duration and severity of anticipating fear, CAS, GAS, CGI, HAM-D, adverse effects and the number of capsules not taken were noted. Fluvoxamine was not significantly superior to placebo with regard to the main outcome criterion, i.e., the reduction in the number of panic attacks, but it was s…

AdultMaleAdolescentFluvoxaminePlacebolaw.inventionRandomized controlled trialDouble-Blind Methodlawmental disordersmedicineHumansPharmacology (medical)Adverse effectAgedPsychiatric Status Rating ScalesPanic disorderPanicGeneral MedicineMiddle Agedmedicine.diseasehumanitiesPsychiatry and Mental healthAnti-Anxiety AgentsFluvoxamineAnesthesiaPanic DisorderFemalemedicine.symptomDrug MonitoringPsychologyAnxiety disorderSelective Serotonin Reuptake Inhibitorsmedicine.drugAgoraphobiaPharmacopsychiatry
researchProduct

Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinica…

1999

Combining fluvoxamine and clozapine may be a strategy to improve therapeutic effects on negative symptoms in schizophrenic patients. Fluvoxamine, however, markedly inhibits the metabolism of clozapine, and hazardous side effects may result. This study prospectively investigated the safety and tolerability of an add-on therapy with fluvoxamine to a clozapine monotherapy in schizophrenic patients. Sixteen schizophrenic patients received 50 mg fluvoxamine as a comedication after having reached steady-state conditions under clozapine monotherapy. Patients were monitored for subjective adverse events, laboratory parameters, EEG and ECG recordings, orthostatic hypotension and their psychopatholog…

AdultMaleAdolescentMatched-Pair AnalysisFluvoxamineDrug Administration ScheduleOrthostatic vital signsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesAdverse effectClozapineClozapineTherapeutic effectGeneral MedicineMiddle AgedDrug interactionPsychiatry and Mental healthTreatment OutcomeTolerabilityFluvoxamineAnesthesiaSchizophreniaAntidepressive Agents Second-GenerationDrug Therapy CombinationFemaleDrug MonitoringPsychologyReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Temporal dynamics of hippocampal neurogenesis in chronic neurodegeneration.

2014

Increased neurogenesis has been reported in neurodegenerative disease, but its significance is unclear. In a mouse model of prion disease, Gomez-Nicola et al. detect increased neurogenesis in the dentate gyrus that partially counteracts neuronal loss. Targeting neurogenesis may have therapeutic potential.

AdultMaleAntimetabolites AntineoplasticPatch-Clamp TechniquesTime FactorsPrionsNeurogenesisGenetic VectorsHippocampusTissue BanksBiologyHippocampal formationHippocampusCreutzfeldt-Jakob SyndromePrion DiseasesMiceYoung AdultNeural Stem CellsAlzheimer Diseasevariant CJDNeural PathwaysmedicineAnimalsHumansAgedCell ProliferationDentate gyrusNeurogenesisNeurodegenerationCytarabineNeurodegenerative DiseasesOriginal ArticlesMiddle Agedmedicine.diseaseNeural stem cellMice Inbred C57BLNeuroanatomical Tract-Tracing Techniquesadult neurogenesisDisease Models AnimalChronic DiseaseDentate GyrusMossy Fibers HippocampalDisease ProgressionFemaleNeurology (clinical)Alzheimer's diseaseNeuroscienceNeural developmentAlzheimer’s diseaseBrain : a journal of neurology
researchProduct

Pathological implications of Th1/Th2 cytokine genetic variants in Behçet's disease: Data from a pilot study in a Sicilian population

2013

Cytokines act as pleiotropic polypeptides able to regulate inflammatory/immune responses and to provide important signals in physiological and pathological processes. Several cytokines (Th1, Th2, and Th17) seem to be involved in the pathophysiology of Behçet's disease, a chronic immune-mediated disease characterized by oral and genital lesions and ocular inflammation. Its individual susceptibility seems to be modulated by genetic variants in genes codifying these cytokines. Th1 and Th17 seem to be involved in the disease's active phases, and Th2 seems to affect the development or severity of the disease; however, contrasting data are reported. In this study, some genetic variants of the Th1…

AdultMaleGenotypePopulationPilot ProjectsBehcet's diseaseDiseaseBiologyPolymorphism Single NucleotideBiochemistryYoung AdultImmune systemTh1 and Th2 cytokines Immune imbalance Behc¸et’s disease Polymorphisms SusceptibilityGene FrequencyGenotypeGeneticsmedicineHumansSettore MED/05 - Patologia ClinicaeducationSicilyMolecular BiologyPathologicalEcology Evolution Behavior and SystematicsSettore MED/04 - Patologia Generaleeducation.field_of_studyBehcet SyndromeInterleukinsGenetic VariationGeneral MedicineMiddle Agedmedicine.diseaseHuman geneticsPathophysiologySettore MED/16 - ReumatologiaImmunologyFemale
researchProduct

Effect of serotonin uptake inhibition by zimelidine on hypothalamic-pituitary-adrenal activity

1983

Plasma ACTH levels after oral ingestion of 2 g metyrapone at 24.00 hours in six healthy subjects were higher after pretreatment with zimelidine (300 mg) in comparison to placebo. Since zimelidine is a relatively selective serotonin reuptake inhibitor its action on hypothalamic-pituitary-adrenal (HPA) activity suggests that serotonin is a potent stimulator of ACTH release. The ratio of cortisol to 11-deoxycortisol was taken as a measure of 11-hydroxylase activity, which indicates biological activity of secreted ACTH. These cortisol/11-deoxycortisol ratios were significantly increased after zimelidine treatment, when compared to placebo. Both the ACTH response and the cortisol/11-deoxycortiso…

AdultMaleHypothalamo-Hypophyseal SystemSerotoninendocrine systemmedicine.medical_specialtySerotonin uptakePyridinesSerotonin reuptake inhibitorPituitary-Adrenal SystemPharmacologyPlaceboPlacebosAdrenocorticotropic HormoneInternal medicinemedicineHumansZimelidinePharmacologyMetyraponeChemistryPhysiological conditionZimeldineBiological TransportBiological activityBrompheniramineEndocrinologySerotonin AntagonistsSerotoninhormones hormone substitutes and hormone antagonistsmedicine.drugPsychopharmacology
researchProduct

Infective endocarditis: review of 36 cases

2009

In a retrospective study of cases of infective endocarditis (IE) observed in adult patients, the data of patients hospitalized for definite IE in the Cardiosurgery Unit of ARNAS-Civico in Palermo (Italy) from March 2003 to September 2006 were analysed. All cases were classified according to the modified Duke criteria. In all, 36 immunocompetent patients with "definite" IE were included (20 males and 16 females with a median age of 54 years). The aortic valve (23/36, 64%) was the most commonly involved, followed by the mitral (19/36, 52.7%) and tricuspid valve (4/36, 11%). In 10 patients (27.7%), a double localization was observed. Blood culture yielded a positive result in 15 cases. Staphyl…

AdultMaleInfective endocarditis Staphylococcus aureus Enterococcus faecalis adult risk factorsEndocarditisSettore MED/17 - Malattie InfettiveCandidiasisHeart Valve DiseasesBacteremiaEndocarditis BacterialMiddle AgedCombined Modality TherapyAnti-Bacterial AgentsPostoperative ComplicationsItalyRisk FactorsHumansFemaleImmunocompetenceRetrospective Studies
researchProduct

TheMAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression

2006

This study investigated the possible association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized double-blind controlled clinical trial. Female mirtazapine-treated patients homozygous for the T-allele had a significantly faster and better treatment response than TG/GG-patients. In males, we failed to show an association between MAOA T941G gene variant and mirtazapine response. In the paroxetine-treated group, there were no significant differences in treatment response between MAOA T941G genotype groups. Time course of response and antidepressant eff…

AdultMaleOncologymedicine.medical_specialtyTime FactorsGenotypeGenetic LinkageMirtazapineMirtazapineMianserinPolymorphism Single NucleotideCellular and Molecular NeuroscienceDouble-Blind MethodGene FrequencyInternal medicineGenotypemedicineHumansAlleleMonoamine OxidaseGenotypingGenetics (clinical)Depressive Disorder MajorSex Characteristicsbusiness.industryMiddle AgedParoxetineAntidepressive AgentsClinical trialParoxetinePsychiatry and Mental healthTreatment OutcomeEndocrinologyAntidepressantFemalebusinessReuptake inhibitormedicine.drugAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics
researchProduct

The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease.

2005

Objective: To assess cognitive function in variant Creutzfeldt-Jakob disease (vCJD). We describe the neuropsychological profiles of 10 cases and compare these data with cross sectional data obtained from patients with histologically confirmed sporadic CJD and cases with inherited prion disease with confirmed mutations in the prion protein gene. Methods: Patients referred to the Specialist Cognitive Disorders Clinic at the National Hospital for Neurology and Neurosurgery and the National Prion Clinic at St Mary's Hospital, London for further investigation of suspected CJD were recruited into the study. The neuropsychological test battery evaluated general intelligence, visual and verbal memo…

AdultMalePaperPediatricsmedicine.medical_specialtyPrionsanimal diseasesDNA Mutational AnalysisNeuropsychological TestsCreutzfeldt-Jakob SyndromePrion DiseasesNational Prion Clinicmental disordersmedicineDementiaHumansCognitive declinePsychiatrymedicine.diagnostic_testSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicabusiness.industryNeuropsychologyNeuropsychological testCreutzfeldt-Jakob SyndromeMiddle Agedmedicine.diseasenervous system diseasesPsychiatry and Mental healthCross-Sectional StudiesAdult Cognition Disorders/etiology Creutzfeldt-Jakob Syndrome/complications Creutzfeldt-Jakob Syndrome/genetics Creutzfeldt-Jakob Syndrome/psychology Cross-Sectional Studies DNA Mutational Analysis Disease Progression Female Humans Male Middle Aged Neuropsychological Tests Prion Diseases/genetics Prion Diseases/psychology Prions/genetics Visual PerceptionDisease ProgressionVisual PerceptionSurgeryFemaleNeurology (clinical)Verbal memorybusinessCognition DisordersExecutive dysfunctionJournal of neurology, neurosurgery, and psychiatry
researchProduct

Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients w…

2015

Background The aim of the study was to better characterise the immunological origin and the behaviour of interleukin (IL)-23-responsive innate lymphoid cells (ILCs) in the gut, synovial fluid (SF) and bone marrow (BM) of patients with ankylosing spondylitis (AS).Methods ILC1, ILC2 and ILC3 cells were determined and characterised by confocal microscopy and flow cytometry in ileal and BM biopsies, in peripheral blood (PB) and SF mononuclear cells obtained from patients with AS and controls. Mucosal vascular addressin cell adhesion molecule 1 (MADCAM-1), IL-7, IL-15 and aggregates of lymphoid tissue inducer cells (LTi) were evaluated by immunohistochemistry. The in vitro ability of epithelial …

AdultMalePathologymedicine.medical_specialtyAdolescentImmunologyHigh endothelial venulesImmunoglobulinsPeripheral blood mononuclear cellGeneral Biochemistry Genetics and Molecular BiologyInterleukin 22Young AdultMucoproteinsAnkylosing Spondylitis; Cytokines; InflammationRheumatologyBone MarrowIleumSynovial FluidAddressinImmunology and AllergyMedicineSynovial fluidHumansSpondylitis AnkylosingLymphocytesIntestinal MucosaCytokineAgedInterleukin-15InflammationMicroscopy ConfocalAnkylosing SpondylitibiologyNatural Cytotoxicity Triggering Receptor 2business.industryInterleukin-7InterleukinsInnate lymphoid cellInterleukin-17Middle AgedSettore MED/16 - Reumatologiamedicine.anatomical_structureLymphatic systemCase-Control Studiesbiology.proteinFemaleBone marrowbusinessCell Adhesion Molecules
researchProduct